Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
421 participants
OBSERVATIONAL
2018-07-02
2020-03-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis
NCT03011281
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
NCT06016517
Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate
NCT00235859
Comparative Effectiveness of Targeted Therapy in RA Patients
NCT04449224
Quality of Life Study With Adalimumab in Rheumatoid Arthritis
NCT00234936
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study design: Non-interventional, multi-centers, cross-sectional study
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
tofacitinib citrate users
patients who have been using tofacitinib citrate for 6 months or more and less than 2 year in RA patients
No interventions assigned to this group
adalimumab users
patients who have been using adalimumab for 6 months or more and less than 2 year in RA patients
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients diagnosed with RA
3. Treatment groups:
1\) Tofacitinib citrate users: Patients currently on treatment with tofacitinib citrate in RA therapy for 6 months or more 2) Adalimumab users: Patients currently on treatment with adalimumab in the RA therapy for 6 months or more 4. Reading and writing with enough proficiency to complete assessment instruments in Korean
Exclusion Criteria
2. Patients taking Azathioprine and cyclosporine
3. Patients participating in other drug interventional study
4. Patients who have been treated with bDMARDs except Rheumatoid arthritis.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kyung Hee University Hospital at Gangdong / Rheumatology
Seoul, Gangdong-gu, South Korea
Chonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea
Wonkwang University Hospital / Division of Rheumatology
Iksan, Jeonlabuk-do, South Korea
Ajou University Hospital, Department of Rheumatology
Suwon, Kyeongki-do, South Korea
Eulji University Hospital
Daejeon, Republic of Korea, South Korea
Asan Medical Center
Songpa-gu, Seoul, South Korea
Hallym University Sacred Heart Hospital/Rheumatology, Internal Medicine
Anyang, , South Korea
Inje University Busan Paik Hospital, Department of Internal Medicine
Busan, , South Korea
Kosin University Gospel Hospital
Busan, , South Korea
Keimyung University Dongsan Medical Center
Daegu, , South Korea
Daegu Catholic University Medical Center, Department of Rheumatology
Daegu, , South Korea
Gacheon Medical School Gil Medical Center, Rheumatology, Internal Medicine
Incheon, , South Korea
Pusan National University Hospital
Pusan, , South Korea
Dong-A University Hospital
Pusan, , South Korea
Hanyang University Seoul Hospital
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Yonsei University Severance Hospital
Seoul, , South Korea
Kyung Hee University Hospital
Seoul, , South Korea
Hanyang University Hospital, Department of Rheumatology
Seoul, , South Korea
Catholic University of Korea, Kangnam St. Mary's Hospital
Seoul, , South Korea
Konkuk University Hospital, Department of Rheumatology
Seoul, , South Korea
Chung-Ang University Hospital
Seoul, , South Korea
Ewha Womans University Mokdong Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kim SK, Lee SH, Sun J, Lee SH, Jeon JY, Yoo HJ, Choe JY. Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab. Arthritis Res Ther. 2023 Apr 27;25(1):68. doi: 10.1186/s13075-023-03047-1.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RA SATISFACTION
Identifier Type: OTHER
Identifier Source: secondary_id
A3921304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.